Cyclerion Therapeutics, Inc.

CYCN
$3.12 (+ $0.12 + 3.83%)
Last updated: 2026-06-10 19:07 UTC
CYCN Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS23255M1053
CUSIP23255M105
Market Price3.12
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.77
Market Cap$7.4M
Book Value2.58
Price to Book0.539
Beta0.96
52w High6.25
52w Low1.16
Next Earnings DateN/A

Cyclerion Therapeutics, Inc. trades under ticker CYCN on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US23255M1053, CUSIP 23255M105. Also searched as Cyclerion Therapeutics.

Related researchCYCN stock priceCYCN share priceCyclerion Therapeutics stockCyclerion Therapeutics share price23255M105
About the Company
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Price History